You can buy or sell CBAY and other stocks, options, ETFs, and crypto commission-free!
CymaBay Therapeutics Inc. Common Stock, also called CymaBay Therapeutics, is a clinical stage biopharmaceutical company, focused on developing and providing access to therapies for patients with liver and other chronic diseases with high unmet medical need. Read More Its products include MBX-8025 and Arhalofenate, MBX-8025 aims to treat lipid and liver diseases while Arhalofenate intends to reduce gout flares and serum uric acid. The company was founded on October 5, 1988 and is headquartered in Newark, CA.
52 Week High
52 Week Low
Research And Development
Yahoo FinanceMay 9
Hedge Funds Have Never Been This Bullish On CymaBay Therapeutics Inc
Does CymaBay Therapeutics Inc (NASDAQ:CBAY) represent a good buying opportunity at the moment? Let’s briefly check the hedge fund interest towards the company. Hedge fund firms constantly search out bright intellectuals and highly-experienced employees and throw away millions of dollars on satellite photos and other research activities, so it is no wonder why they tend to generate millions in profits each year. It is also true that some hedge fund players fail inconceivably on some occasions, but net net th...
Seeking AlphaMay 9
CymaBay Therapeutics' (CBAY) CEO Sujal Shah on Q1 2019 Results - Earnings Call Transcript
CymaBay Therapeutics, Inc. (NASDAQ:CBAY) Q1 2019 Results Earnings Conference Call May 8, 2019 4:30 PM ET Company Participants Dan Menold – Vice President of Finance Sujal Shah – Chief Executive Officer Chuck McWherter – Chief Scientific Officer Pol Boudes – Chief Medical Officer Conference Call Participants Yasmeen Rahimi – Roth Capital Partners Ellie Merle – Cantor Fitzgerald Mike Kratky – SVB Leerink Steve Seedhouse – Raymond James Jay Olson – Oppenheimer Ed Arce – H.C. Wainwright Jeffrey – w...
Yahoo FinanceMay 2
Genfit, Cymbay Hope to Crack Large Liver Disease Market
- By Barry Cohen Investors seeking to find the next great pharmaceutical company may want to concentrate on emerging biopharma. The smaller members of the group are driving growth in research. Moreover, they have less need for a partner or to be acquired to develop their drugs, according to a report by health care research firm IQVIA (IQVA). About two of every three patents on drugs launched last year were awarded to emerging biopharmas . According to the report, they also accounted for nearly the...
Expected Aug 8, After Hours